Rüdiger Müller
Long-Term Increase of Radiographic Damage and Disability in Patients with RA in Relation to Disease Duration in the Era of Biologics. Results from the SCQM Cohort
Heinimann K, von Kempis J, Sauter R, Schiff M, Sokka-Isler T, Schulze-Koops H, Müller R. Long-Term Increase of Radiographic Damage and Disability in Patients with RA in Relation to Disease Duration in the Era of Biologics. Results from the SCQM Cohort. J Clin Med 2018; 7
13.03.2018Long-Term Increase of Radiographic Damage and Disability in Patients with RA in Relation to Disease Duration in the Era of Biologics. Results from the SCQM Cohort
13.03.2018J Clin Med 2018; 7
Heinimann Katja, von Kempis Johannes, Sauter Rafael, Schiff Michael, Sokka-Isler Tuulikki, Schulze-Koops Hendrik, Müller Rüdiger
Disease activity dynamics in rheumatoid arthritis: patients' self-assessment of disease activity via WebApp
Walker U, Müller R, Jaeger V, Theiler R, Forster A, Dufner P, Ganz F, Kyburz D. Disease activity dynamics in rheumatoid arthritis: patients' self-assessment of disease activity via WebApp. Rheumatology (Oxford) 2017; 56:1707-1712.
01.10.2017Disease activity dynamics in rheumatoid arthritis: patients' self-assessment of disease activity via WebApp
01.10.2017Rheumatology (Oxford) 2017; 56:1707-1712
Walker Ulrich, Müller Rüdiger, Jaeger Veronika, Theiler Robert, Forster Adrian, Dufner Patrick, Ganz Fabiana, Kyburz Diego
Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis
Alpizar-Rodriguez D, Gabay C, Courvoisier D, Lamacchia C, Mahler M, Roux-Lombard P, Von Mühlenen I, Walker U, Kyburz D, Zufferey P, Ciurea A, Dudler J, Möller B, Müller R, Finckh A. Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis. Rheumatology (Oxford) 2017; 56:1579-1585.
01.09.2017Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis
01.09.2017Rheumatology (Oxford) 2017; 56:1579-1585
Alpizar-Rodriguez Deshiré, Gabay Cem, Courvoisier Delphine S, Lamacchia Céline, Mahler Michael, Roux-Lombard Pascale, Von Mühlenen Ines, Walker Ulrich A, Kyburz Diego, Zufferey Pascal, Ciurea Adrian, Dudler Jean, Möller Burkhard, Müller Rüdiger, Finckh Axel
Treatment with Biologicals in Rheumatoid Arthritis: An Overview
Rein P, Müller R. Treatment with Biologicals in Rheumatoid Arthritis: An Overview. Rheumatology and Therapy 2017; 4:247-261.
22.08.2017Treatment with Biologicals in Rheumatoid Arthritis: An Overview
22.08.2017Rheumatology and Therapy 2017; 4:247-261
Rein Philipp, Müller Rüdiger
Treatment with Biologicals in Rheumatoid Arthritis: An Overview
Rein P, Müller R. Treatment with Biologicals in Rheumatoid Arthritis: An Overview. Rheumatol Ther 2017; 4:247-261.
22.08.2017Treatment with Biologicals in Rheumatoid Arthritis: An Overview
22.08.2017Rheumatol Ther 2017; 4:247-261
Rein Philipp, Müller Rüdiger
Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study
Müller R, Graninger W, Sidiropoulos P, Goger C, von Kempis J. Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study. Clin Rheumatol 2017; 36:2187-2192.
03.08.2017Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study
03.08.2017Clin Rheumatol 2017; 36:2187-2192
Müller Rüdiger, Graninger Winfried, Sidiropoulos Paris, Goger Christoph, von Kempis Johannes
Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study
Müller R, Graninger W, Sidiropoulos P, Goger C, von Kempis J. Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study. Clin Rheumatol 2017; 36:2187-2192.
03.08.2017Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study
03.08.2017Clin Rheumatol 2017; 36:2187-2192
Müller Rüdiger, Graninger Winfried, Sidiropoulos Paris, Goger Christoph, von Kempis Johannes
Blue-Finger-Syndrome and Tofacitinib
Popp F, Benecke U, Fischer S, von Kempis J, Koeger P, Müller R. Blue-Finger-Syndrome and Tofacitinib - Case Report. Clinical Image: Annals of Clinical Case Reports 2017; 2
18.07.2017Blue-Finger-Syndrome and Tofacitinib
18.07.2017Clinical Image: Annals of Clinical Case Reports 2017; 2
Popp Florian, Benecke U, Fischer S, von Kempis Johannes, Koeger P, Müller Rüdiger
Granuloma Annulare, Drug-Induced Lupus and
Popp F, Fischer S, Kempf W, von Kempis J, Welcker M, Müller R. Granuloma Annulare, Drug-Induced Lupus and - Case Report. Clinical Image: Annals of Clinical Case Reports 2017; 2
17.04.2017Granuloma Annulare, Drug-Induced Lupus and
17.04.2017Clinical Image: Annals of Clinical Case Reports 2017; 2
Popp Florian, Fischer S, Kempf W, von Kempis Johannes, Welcker M, Müller Rüdiger
The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis
Alpizar-Rodriguez D, Bas S, Gascon D, Lamacchia C, Roux-Lombard P, Lauper K, Nissen M, Courvoisier D, Gabay C, Mahler M, Zufferey P, Brulhart L, Müller R, Möller B, Dudler J, Ciurea A, Walker U, Von Mühlenen I, Kyburz D, Finckh A. The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis. Clin Rheumatol 2017
21.01.2017The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis
21.01.2017Clin Rheumatol 2017
Alpizar-Rodriguez D, Bas Sylvette, Gascon Danielle, Lamacchia Céline, Roux-Lombard Pascale, Lauper Kim, Nissen Michael J, Courvoisier Delphine S, Gabay Cem, Mahler Michael, Zufferey Pascal, Brulhart Laure, Müller Rüdiger, Möller Burkhard, Dudler Jean, Ciurea Adrian, Walker Ulrich A, Von Mühlenen Ines, Kyburz Diego, Finckh Axel
Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM)
Müller R, von Kempis J, Spaeth M, Schiff M, Schulze-Koops H, Haile S, Finckh A, Kaegi T, Reshiti N. Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM). Clin Rheumatol 2016; 36:59-66.
12.11.2016Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM)
12.11.2016Clin Rheumatol 2016; 36:59-66
Müller Rüdiger, von Kempis Johannes, Spaeth Michael, Schiff Michael, Schulze-Koops Hendrik, Haile Sarah R, Finckh Axel, Kaegi Toni, Reshiti Nazim
Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK)
Müller R, Gengenbacher M, Richter S, Dudler J, Möller B, von Kempis J. Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK). Arthritis Res Ther 2016; 18:88.
14.04.2016Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK)
14.04.2016Arthritis Res Ther 2016; 18:88
Müller Rüdiger, Gengenbacher Michael, Richter Symi, Dudler Jean, Möller Burkhard, von Kempis Johannes
Postoperative Fasziendehiszenz unter kombinierter Immunmodulation mit Methotrexat, Prednison und Abatacept
Müller R. Postoperative Fasziendehiszenz unter kombinierter Immunmodulation mit Methotrexat, Prednison und Abatacept. Swiss Medical Forum 2016; 15:114-115.
19.01.2016Postoperative Fasziendehiszenz unter kombinierter Immunmodulation mit Methotrexat, Prednison und Abatacept
19.01.2016Swiss Medical Forum 2016; 15:114-115
Müller Rüdiger
Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort
Müller R, von Kempis J, Haile S, Schiff M. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort. Semin Arthritis Rheum 2015; 45:28-34.
03.03.2015Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort
03.03.2015Semin Arthritis Rheum 2015; 45:28-34
Müller Rüdiger, von Kempis Johannes, Haile Sarah, Schiff Michael H
The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritis
Müller R, Schiff M, Kaegi T, Finckh A, Haile S, Schulze-Koops H, von Kempis J, Swiss Clinical Quality Management (SCQM) physicians. The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritis. Clin Rheumatol 2014; 34:51-9.
15.07.2014The new 2010 ACR/EULAR criteria as predictor of clinical and radiographic response in patients with early arthritis
15.07.2014Clin Rheumatol 2014; 34:51-9
Müller Rüdiger, Schiff M, Kaegi T, Finckh A, Haile Sarah, Schulze-Koops H, von Kempis Johannes, Swiss Clinical Quality Management (SCQM) physicians
The advent of biosimilars: challenges and risks
Müller R, Renner C, Gabay C, Cassata G, Lohri A, Hasler P. The advent of biosimilars: challenges and risks. Swiss Med Wkly 2014; 144:w13980.
01.07.2014The advent of biosimilars: challenges and risks
01.07.2014Swiss Med Wkly 2014; 144:w13980
Müller Rüdiger, Renner Christoph, Gabay Cem, Cassata Giuseppe, Lohri Andreas, Hasler Paul
Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase
Schiff M, von Kempis J, Goldblum R, Tesser J, Müller R. Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase. Ann Rheum Dis 2014; 73:2174-7.
27.06.2014Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase
27.06.2014Ann Rheum Dis 2014; 73:2174-7
Schiff Michael H, von Kempis Johannes, Goldblum Ronald, Tesser John R, Müller Rüdiger
Is radiographic progression of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis? Results from the Swiss prospective observational cohort
Müller R, Kaegi T, Finckh A, Haile S, Schulze-Koops H, von Kempis J, on behalf of the SCQM physicians. Is radiographic progression of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis? Results from the Swiss prospective observational cohort. Rheumatology (Oxford) 2013
17.12.2013Is radiographic progression of late-onset rheumatoid arthritis different from young-onset rheumatoid arthritis? Results from the Swiss prospective observational cohort
17.12.2013Rheumatology (Oxford) 2013
Müller Rüdiger, Kaegi Toni, Finckh Axel, Haile Sarah, Schulze-Koops Hendrik, von Kempis Johannes, on behalf of the SCQM physicians
Tumor necrosis factor-alpha inhibition in radiographic and non-radiographic axial spondyloarthritis: results from a large observational cohort
Müller R. Tumor necrosis factor-alpha inhibition in radiographic and non-radiographic axial spondyloarthritis: results from a large observational cohort. Arthritis Rheum 2013; 2013:3096-3106.
14.12.2013Tumor necrosis factor-alpha inhibition in radiographic and non-radiographic axial spondyloarthritis: results from a large observational cohort
14.12.2013Arthritis Rheum 2013; 2013:3096-3106
Müller Rüdiger
Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort
Ciurea A, Weber U, Boonen A, Dougados M, van der Heijde D, Michel B, Nissen M, Müller R, Weiss B, Tamborrini G, Rufibach K, Stekhoven D, Kissling R, Beyeler B, Dudler J, Bernhard J, Exer P, Scherer A, Rheumatologists of the Swiss Clinical Quality Management Program for Axial Spondyloarthritis. Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort. Arthritis Rheum 2013; 65:3096-106.
01.12.2013Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort
01.12.2013Arthritis Rheum 2013; 65:3096-106
Ciurea Adrian, Weber Ulrich, Boonen Annelies, Dougados Maxime, van der Heijde Désirée, Michel Beat A, Nissen Michael J, Müller Rüdiger, Weiss Bettina, Tamborrini Giorgio, Rufibach Kaspar, Stekhoven Daniel, Kissling Rudolf, Beyeler Brigitte, Dudler Jean, Bernhard Jürg, Exer Pascale, Scherer Almut, Rheumatologists of the Swiss Clinical Quality Management Program for Axial Spondyloarthritis